Abstract 2739
Background
Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors approved in the EU and other countries in combination with docetaxel for treatment of locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after 1st line chemotherapy. Data are sparse regarding efficacy and safety of nintedanib in adenocarcinoma pts who had been pre-treated with ICIs.
Methods
This interim analysis included 32 pts with locally advanced, metastatic or locally recurrent lung adenocarcinoma who received nintedanib and docetaxel in 3rd line following ICIs in 2nd line within the ongoing NIS VARGADO (cohort B); it updates and extends data previously presented at ESMO IO 2018.
Results
Median age was 60 years (range: 45 – 76), 21/32 pts (65.6%) were men, and 22/32 pts (68.8%) were ECOG PS0/1. 7/32 pts (21.9%) had brain metastases, and 25/32 pts (78.1%) were current or former smokers. 1st line chemotherapy treatments included pemetrexed (23/32 pts, 71.9%), cisplatin (20/32 pts, 62.5%), carboplatin (16/32 pts, 50.0%), bevacizumab (9/32 pts, 28.1%), vinorelbine (5/32 pts, 15.6%), paclitaxel (2/32 pts, 6.3%), and docetaxel (1/32 pts, 3.1%). 2nd line treatments included nivolumab (21/32 pts, 65.6%), pembrolizumab (7/32 pts, 21.9%), and atezolizumab (3/32 pts, 9.4%). Under nintedanib and docetaxel, 12/24 pts (50.0%) developed a partial response and 7/24 pts (29.2%) showed stable disease; DCR was 79.2% (19/24 pts). Median PFS was 7.1 months (95%CI 2.9 – 8.2). Treatment emergent adverse events (TEAEs) grade ≥3, serious TEAEs, and TEAEs leading to discontinuation were observed in 18/32 pts (56.3%), 16/32 pts (50.0%), and 12/32 pts (37.5%), respectively.
Conclusions
In this updated analysis, nintedanib in combination with docetaxel showed clinically relevant efficacy and an adequate safety profile in stage IIIB/IV lung adenocarcinoma pts following treatment with chemotherapy and ICIs. Data highlight the potential clinical benefit of rational treatment sequencing with anti-angiogenic therapy after ICIs.
Clinical trial identification
NCT02392455.
Editorial acknowledgement
Legal entity responsible for the study
Boehringer Ingelheim Pharma GmbH & Co. KG.
Funding
Boehringer Ingelheim Pharma GmbH & Co. KG.
Disclosure
C. Grohe: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. W. Gleiber: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. S. Krüger: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. M. Schulze: Advisory / Consultancy, Membership on advisory board: Boehringer Ingelheim. J. Atz: Full / Part-time employment: Boehringer Ingelheim. R. Kaiser: Full / Part-time employment: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract
5314 - Spirituality and religious coping for Cancer patients and providers: An ‘Almighty’ belief for palliative care
Presenter: Vibhay Pareek
Session: Poster Display session 1
Resources:
Abstract